Get access
Journal of Cellular Biochemistry

Assessing iPSC reprogramming methods for their suitability in translational medicine

Authors

  • Mahendra S. Rao,

    Corresponding author
    1. National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Laboratory of Stem Cell Biology, Bethesda, Maryland
    2. National Institutes of Health Center for Regenerative Medicine, Bethesda, Maryland
    • National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Laboratory of Stem Cell Biology, Bethesda, MD 20892; National Institutes of Health Center for Regenerative Medicine, Bethesda, MD 20892.
    Search for more papers by this author
  • Nasir Malik

    1. National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Laboratory of Stem Cell Biology, Bethesda, Maryland
    Search for more papers by this author

Abstract

The discovery of the ability to induce somatic cells to a pluripotent state through the overexpression of specific transcription factors has the potential to transform the ways in which pharmaceutical agents and cellular transplantation therapies are developed. Proper utilization of the technology to generate induced pluripotent stem cells (iPSCs) requires that researchers select the appropriate reprogramming method for generating iPSCs so that the resulting iPSCs can be transitioned towards clinical applications effectively. This article reviews all of the currently available reprogramming techniques with a focus on critiquing them on the basis of their utility in translational medicine. J. Cell. Biochem. 113: 3061-3068, 2012. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.

Get access to the full text of this article

Ancillary